OSUR · OraSure Technologies, Inc.

This filing relates to an ongoing activist campaign by Altai Capital Management, which is seeking to replace two independent directors on OraSure’s board. The Exhibit 99.1 presentation refutes Altai’s claims of poor operational performance and value-destructive capital allocation, noting OraSure has outperformed Altai’s selected peer median by ~40% during CEO Carrie Eglinton Manner’s tenure. The company reports it is on track for operating cash flow breakeven in H1 2026, holds a debt-free balance sheet with $199 million in cash as of end-2025, and has near-term product milestones including pending FDA review for its Sherlock CT/NG molecular self-test targeting a $1.5 billion STI market. OraSure’s board rejected Altai’s demand for a seat for founder Rishi Bajaj citing his limited operational value creation track record, while offering Altai an independent director seat and confidential information access that was rejected.